Nektar Therapeutics
Oligomer-beta blocker conjugates
Last updated:
Abstract:
The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
Status:
Grant
Type:
Utility
Filling date:
15 Feb 2019
Issue date:
5 Jan 2021